ALVO
$3.53-0.05 (-1.40%)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Recent News
Did Alvotech’s (ALVO) Profitability Turn and Expanding Biosimilar Pipeline Just Recast Its Investment Narrative?
Alvotech recently reported full-year 2025 results, swinging to net income of US$27.92 million from a prior-year net loss of US$231.86 million, alongside updates on FDA feedback, global biosimilar launches, and new commercialization agreements. The combination of returning to profitability, advancing a 30-product biosimilar pipeline, and reaffirming 2026 guidance highlights a business model becoming more diversified across products, partners, and regions. We’ll now examine how Alvotech’s...
Alvotech Q4 Earnings Call Highlights
Alvotech (NASDAQ:ALVO) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline progress on commercial launches, manufacturing and quality initiatives tied to recent U.S. regulatory setbacks, and a 2026 outlook that assumes continued growth outside the United States.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Rising Oil Prices, Reduced Rate-Cut Expectations
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4%, and the actively t
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Look For
This article first appeared on GuruFocus. Alvotech (NASDAQ:ALVO) is set to release its Q4 2025 earnings on Mar 19, 2026. The consensus estimate for Q4 2025 revenue is $0.16 billion, and the earnings are expected to come in at -$0.20 per share.
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect
This article first appeared on GuruFocus. Alvotech (NASDAQ:ALVO) is set to release its Q4 2025 earnings on March 18, 2026. The consensus estimate for Q4 2025 revenue is $0.16 billion, and the earnings are expected to come in at -$0.20 per share.